StreetAlpha.app
Home › Stocks › CATX

Perspective Therapeutics, Inc. (CATX)

Healthcare
$0.86
▼ −9.11%
LAST CLOSE · NOV 17

Perspective Therapeutics develops cancer drugs that deliver targeted radiation to tumors, paired with imaging tools to guide treatment. It last closed at $0.86 on Nov 17, down 9.11% on the day. The average 12-month price target from 4 analysts is $6.75 (+685.9% from the last close), with a high of $8.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $116K, the largest $116K.

AI Auto Pilots
Is CATX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$122.9M
EPS (diluted)
−$1.25
Free cash flow
−$138.8M
Valuation
Market cap
$103.7M
120.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.0M
At Sep 30
Debt
$1.6M
At Sep 30
Shareholder equity
$294.7M
Shares outstanding
120.8M
At Nov 4
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2022: −$7.3M−$7.3MFY2022FY2022: −$10.8M−$10.8MFY2022FY2023: −$46.5M−$46.5MFY2023FY2024: −$79.3M−$79.3MFY2024FY2025: −$103.1M−$103.1MFY2025

From CATX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on CATX in the past 90 days
Average 12-month target
$6.75
▲ 685.9% upside

Based on 4 analysts who set a price target on CATX in the past 90 days. The average target is $6.75, with a high of $8.00 and a low of $4.00, compared with the last close of $0.86.

Low $4.00Avg $6.75High $8.00
Blue marker: last close $0.86
Highest target$8.00
Average target$6.75
Lowest target$4.00
Latest rating changes
Truist SecuritiesMaintained
Nov 10Buy$8
WedbushTarget lowered
Nov 10Buy$11 → $7
Piper SandlerTarget lowered
Nov 10Buy$14 → $8
RBC CapitalDowngrade
Oct 26Hold$4
WedbushReiterated
Sep 15Buy$11
DateFirmActionRatingPrice target
Nov 10Truist SecuritiesMaintainedBuy$8
Nov 10WedbushTarget loweredBuy$11 → $7
Nov 10Piper SandlerTarget loweredBuy$14 → $8
Oct 26RBC CapitalDowngradeHold$4
Sep 15WedbushReiteratedBuy$11
Loading…

Technical Analysis

CATX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 32% below its 20 day and 135% below its 50 day average. It is 297% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $0.80, and the nearest resistance the Pivot at $0.87.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 18.5%/day
Key levels
$6.1652 week high+616.3%
$3.41200 day average+296.5%
$2.58100 day average+200.0%
$2.40Swing high (Oct 23)+179.1%
$2.0250 day average+134.9%
$1.1320 day average+31.4%
$0.93Pivot R1+8.1%
$0.87Pivot+1.2%
$0.86Last close
$0.80Pivot S1−7.0%
$0.7852 week low−9.3%
$0.78Swing low (Nov 10)−9.3%
Indicators
RSI (14)27.81Oversold below 30Oversold
MACD-0.36Above its signal lineBullish
Stochastic27.9Middle of its rangeNeutral
ADX (14)50.6Strong downtrend
Williams %R-83.9Oversold below −80, overbought above −20Oversold
CCI (20)-59.2Oversold below −100, overbought above 100Neutral
Rate of change−2.0%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 18.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CATX

What happened before

See how CATX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CATX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CATX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CATX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$116K
Largest print
$116K
Loading…

CATX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●58 buying vs 59 selling
  • ▼Held by funds -7.8 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding120132−9.1%
In funds' top 10330.0%
Held by funds66.3%74.2%−7.8 pts
New / increased14 / 4423 / 59−29.3%
Reduced / sold out35 / 2427 / 30+3.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CATX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CATX is in one of them and how their past CATX trades turned out.

CATX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CATX in an article yet. Here's the latest on the wider market.

About Perspective Therapeutics

Perspective Therapeutics is a radiopharmaceutical development company based in Seattle, Washington. It is developing cancer treatments that attach a radioactive isotope known as lead 212 to targeting molecules, which are designed to carry radiation directly to cancer cells. The company also develops imaging agents using a related isotope so that doctors can locate tumors before treatment. Its lead candidates are in clinical trials in the United States for neuroendocrine tumors, melanoma and other solid tumors. The intended users of these treatments are cancer patients and the clinicians who treat them, and the company is building its own manufacturing capacity.

Headquarters
Seattle, WA